Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibility  by Watanabe, Akira et al.
SURVEILLANCE
Nationwide surveillance of bacterial respiratory pathogens
conducted by the Surveillance Committee of Japanese Society
of Chemotherapy, Japanese Association for Infectious Diseases,
and Japanese Society for Clinical Microbiology in 2009: general
view of the pathogens’ antibacterial susceptibility
Akira Watanabe • Katsunori Yanagihara • Tetsuya Matsumoto • Shigeru Kohno • Nobuki Aoki • Toyoko Oguri •
Junko Sato • Tetsuro Muratani • Morimasa Yagisawa • Kazuhiko Ogasawara • Naoto Koashi • Tsuneo Kozuki •
Akira Komoto • Yoshisaburo Takahashi • Toshikatsu Tsuji • Michinori Terada • Kunio Nakanishi •
Rikizo Hattori • Yukio Hirako • Akinori Maruo • Shinichi Minamitani • Kohei Morita • Tomotaro Wakamura •
Keisuke Sunakawa • Hideaki Hanaki • Yoshinobu Ohsaki • Yasuhito Honda • Shoichi Sasaoka • Hiroaki Takeda •
Hideki Ikeda • Atsuko Sugai • Makoto Miki • Susumu Nakanowatari • Hiroshi Takahashi • Mutsuko Utagawa •
Nobuyuki Kobayashi • Jin Takasaki • Hisami Konosaki • Yasuko Aoki • Michi Shoji • Hajime Goto •
Takeshi Saraya • Daisuke Kurai • Mitsuhiro Okazaki • Yoshio Kobayashi • Yasuhiro Katono • Akihiko Kawana •
Katsu Saionji • Naoki Miyazawa • Yoshimi Sato • Yuji Watanuki • Makoto Kudo • Shigeru Ehara •
Hiroki Tsukada • Yumiko Imai • Nobuei Watabe • Sakura Aso • Yasuo Honma • Hiroshige Mikamo •
Yuka Yamagishi • Yoshio Takesue • Yasunao Wada • Tadahiro Nakamura • Noriko Mitsuno • Keiichi Mikasa •
Kei Kasahara • Kenji Uno • Reiko Sano • Naoyuki Miyashita • Yukinori Kurokawa • Mariko Takaya •
Masao Kuwabara • Yaeko Watanabe • Masao Doi • Satomi Shimizu • Kiyoshi Negayama • Junichi Kadota •
Kazufumi Hiramatsu • Yoshitomo Morinaga • Junichi Honda • Masaki Fujita • Satoshi Iwata • Aikichi Iwamoto •
Takayuki Ezaki • Shoichi Onodera • Shinya Kusachi • Kazuhiro Tateda • Michio Tanaka • Kyoichi Totsuka •
Yoshihito Niki • Tetsuro Matsumoto
Received: 13 February 2012 / Accepted: 10 May 2012 / Published online: 6 July 2012
 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2012
Abstract For the purpose of nationwide surveillance of
antimicrobial susceptibility of bacterial respiratory patho-
gens from patients in Japan, the Japanese Society of Che-
motherapy (JSC) started a survey in 2006. From 2009, JSC
continued the survey in collaboration with the Japanese
Association for Infectious Diseases and the Japanese
Society for Clinical Microbiology. The fourth-year survey
was conducted during the period from January and April
2009 by the three societies. A total of 684 strains were
collected from clinical specimens obtained from well-
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diagnosed adult patients with respiratory tract infections.
Susceptibility testing was evaluable with 635 strains (130
Staphylococcus aureus, 127 Streptococcus pneumoniae, 4
Streptococcus pyogenes, 123 Haemophilus inﬂuenzae, 70
Moraxella catarrhalis, 78 Klebsiella pneumoniae, and 103
Pseudomonas aeruginosa). A maximum of 45 antibacterial
agents including 26 b-lactams (four penicillins, three
penicillins in combination with b-lactamase inhibitors, four
oral cephems, eight parenteral cephems, one monobactam,
ﬁve carbapenems, and one penem), four aminoglycosides,
four macrolides (including ketolide), one lincosamide, one
tetracycline, two glycopeptides, six ﬂuoroquinolones, and
one oxazolidinone were used for the study. Analysis was
conducted at the central reference laboratory according to
the method recommended by the Clinical and Laboratory
Standard Institute (CLSI). Incidence of methicillin-resis-
tant S. aureus (MRSA) was as high as 58.5 %, and that of
penicillin-intermediate and penicillin-resistant S. pneumo-
niae (PISP and PRSP) was 6.3 % and 0.0 %, respectively.
Among H. inﬂuenzae, 21.1 % of them were found to be
b-lactamase-non-producing ampicillin (ABPC)-intermedi-
ately resistant (BLNAI), 18.7 % to be b-lactamase-
non-producing ABPC-resistant (BLNAR), and 5.7 % to be
b-lactamase-producing ABPC-resistant (BLPAR) strains.
A high frequency (76.5 %) of b-lactamase-producing
strains has been suspected in Moraxella catarrhalis iso-
lates. Four (3.2 %) extended-spectrum b-lactamase-pro-
ducing K. pneumoniae were found among 126 strains. Four
isolates (2.5 %) of P. aeruginosa were found to be metallo-
b-lactamase-producing strains, including three (1.9 %)
suspected multi-drug resistant strains showing resistance
against imipenem, amikacin, and ciproﬂoxacin. Continuous
national surveillance of the antimicrobial susceptibility of
respiratory pathogens is crucial to monitor changing
patterns of susceptibility and to be able to update treatment
recommendations on a regular basis.
Keywords Surveillance  Susceptibility  Resistance 
Respiratory tract infection
Introduction
To investigate comprehensively the antimicrobial suscepti-
bility and resistance of bacterial respiratory pathogens, the
Japanese Society of Chemotherapy (JSC) established a
nationwide surveillance network in 2006. The ﬁrst and sec-
ond surveys were conducted during the period from January
to August in 2006 and 2007 and the third survey was con-
ducted during the period from January to April in 2008; we
reported the trend of antimicrobial susceptibilities of bacte-
rial species from patients with respiratory tract infections
(RTIs) [1]. After a third year of study, we decided to continue
this survey in association with JSC, the Japanese Association
for Infectious Diseases, and the Japanese Society for Clinical
Microbiology. Here we report the study in the fourth year of
nationwide surveillance conducted by the three societies. The
results obtained from this surveillance will be used as a set of
controls for those conducted in future by the three societies
and by other organizations as well.
Materials and methods
Strains and quality control
The causative bacteria from the patients with RTI were
isolated from sputum, specimens collected by transtracheal
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aspiration, or bronchoscopy. Microbiological laboratory
tests for respiratory pathogens were conducted by standard
methods including Gram staining and quantitative culture
of various respiratory samples at 46 medical institutions, as
listed in Table 1. The isolated bacteria were identiﬁed to
species level in each laboratory. The isolates were sus-
pended in Micro-bank tubes (Asuka Junyaku, Tokyo,
Japan) and transferred to the central laboratory of the
Research Center for Anti-infective Drugs of the Kitasato
Institute. The electronic uniform data sheets of each patient
from whom these strains isolated were also completed at
each institution and sent to the Center so that microbio-
logical data obtained could be stratiﬁed under the settings
and proﬁles of patients and under the diagnoses.
A total of 684 strains were received at the Center and
kept at -80 C until antimicrobial susceptibility testing
was conducted. Re-identiﬁcation and cultivation of the
strains gave 635 evaluable strains consisting of 130
Staphylococcus aureus, 127 Streptococcus pneumoniae, 4
Streptococcus pyogenes, 123 Haemophilus inﬂuenzae, 70
Moraxella catarrhalis, 78 Klebsiella pneumoniae, and 103
Pseudomonas aeruginosa.
Accuracy of determination for minimum inhibitory
concentration (MIC) of antibacterial agents was controlled
according to the recommendations of the Clinical and
Laboratory Standards Institute (CLSI) using the following
control strains, respectively: S. aureus ATCC29213 and
Escherichia coli ATCC35218 for clinical isolates of
S. aureus and M. catarrhalis; S. pneumoniae ATCC49619
for those of S. pneumoniae and S. pyogenes; H. inﬂuenzae
ATCC49247 for H. inﬂuenzae; E. coli ATCC25922 for
K. pneumoniae and P. aeruginosa; and P. aeruginosa
ATCC27853 for P. aeruginosa. E. coli ATCC35218 was
used as a control strain in case of MIC determination for
b-lactam antibiotics combined with b-lactamase inhibitors. Susceptibility testing and MIC determination
Susceptibility testing was performed according to CLSI
(formerly NCCLS) standards M7-A7 for the micro-broth
dilution method [2, 3]. In brief, cation-adjusted Mueller–
Hinton broth (25 mg/l Ca2? and 12.5 mg/l Mg2?; CA-MH
broth) was used to measure MIC against S. aureus,
M. catarrhalis, K. pneumoniae, and P. aeruginosa. For
determination of MIC of oxacillin, NaCl was added at 2 %
to CA-MH broth. For measuring MICs against S. pneu-
moniae, S. pyogenes, and H. inﬂuenzae, 15 lg/ml nicotin-
amide, 5 mg/ml yeast extract, and horse blood at 5 % were
added to CA-MH broth.
A 0.005-ml portion of test organism solution, grown to
turbidity at McFarland number 0.5 and diluted tenfold with
saline, was inoculated to CA-MH broth to make a ﬁnal
volume of 0.1 ± 0.02 ml. This solution was poured into a
well on a microplate (Eiken Kagaku, Tokyo, Japan), seri-
ally diluted freeze-dried test agent was added, and the MIC
Table 1 List of participating institutions contributing to our surveillance
Aichi Medical University Hospital, Nagakute, Aichi
Asahikawa Medical University, Asahikawa, Hokkaido
Center for Infectious Diseases, Nara Medical University,
Kashihara, Nara
Fukuoka University Faculty of Medicine, Fukuokas, Fukuoka
Hiroshima Prefectural Hospital, Hiroshima, Hiroshima
Hyogo College of Medicine, Nishinomiya, Hyogo
Japanese Red Cross Sendai Hospital, Sendai, Miyagi
Kagawa University Hospital, Kagawa, Mikicho
Kawasaki Medical School Hospital, Kurashiki, Okayama
Keio University Hospital, Shinjuku, Tokyo
Kyorin University Hospital, Mitaka, Tokyo
Muroran General Hospital, Muroran, Hokkaido
Nagasaki University School of Medicine, Nagasaki, Nagasaki
National Center for Global Health and Medicine, Shinjyuku,
Tokyo
National Defense Medical College, Tokorozawa, Saitama
National Hospital Organization Tokyo Medical Center, Meguro,
Tokyo
Niigata City General Hospital, Niigata, Niigata
Oita University Faculty of Medicine, Yufu, Oita
Osaka City General Hospital, Miyakojima, Osaka
Saka General Hospital, Shiogama, Miyagi
Sanyudo Hospital, Yonezawa, Sanyudo
Sapporo Medical Center NTT EC, Sapporo, Hokkaido
Shinrakuen Hospital, Niigata, Niigata
St. Mary’s Hospital, Kurume, Fukuoka
Yamagata Saisei Hospital, Yamagata, Yamagata
Yokohama City University Hospital, Yokohama, Kanagawa
Yokohama City University Hospital, Yokohama, Kanagawa
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was determined with the MIC2000 system (Eiken Kagaku,
Tokyo, Japan).
Antibacterial agents
The susceptibilities of the bacterial strains were tested for
the following 45 antimicrobial agents: four penicillins such
as benzylpenicillin (PCG; Meiji Seika Kaisha), oxacillin
(MPIPC; Meiji), ampicillin (ABPC; Meiji), and piperacil-
lin (PIPC; Toyama Chemical); three penicillins in combi-
nation with b-lactamase inhibitors such as clavulanic acid-
amoxicillin (CVA/AMPC; Glaxo SmithKline), sulbactam-
ABPC (SBT/ABPC; Pﬁzer Japan), and tazobactam-PIPC
(TAZ/PIPC; Toyama, TAZ/PIPC-1; tazobactam was ﬁxed
at 4 lg/ml; TAZ/PIPC-2; tazobactam/piperacillin was ﬁxed
at 1/8); four oral cephems such as cefaclor (CCL; Shion-
ogi), cefdinir (CFDN; Astellas Pharma), cefcapene (CFPN;
Shionogi), and cefditoren (CDTR; Meiji); eight parenteral
cephems such as cefazolin (CEZ; Astellas), cefoxitin
(CFX; Banyu Pharmaceutical), cefmetazole (CMZ; Daii-
chi-Sankyo), cefotiam (CTM; Takeda Pharmaceutical),
ceftazidime (CAZ; Glaxo SmithKline), ceftriaxone (CTRX;
Chugai Pharmaceutical), cefepime (CFPM; Meiji), and
cefozopran (CZOP; Takeda); a monobactam aztreonam
(AZT; Eisai); ﬁve carbapenems such as imipenem (IPM;
Banyu), panipenem (PAPM; Daiichi-Sankyo), meropenem
(MEPM; Dainippon Sumitomo Pharma), biapenem (BIPM;
Meiji), and doripenem (DRPM; Shionogi); one penem such
as faropenem (FRPM; Maruho); four aminoglycosides
such as gentamicin (GM; Shionogi), tobramycin (TOB;
J-dolph), amikacin (AMK; Banyu), and arbekacin (ABK;
Meiji); four macrolides such as erythromycin (EM;
Dainippon Sumitomo), clarithromycin (CAM; Toyama),
azithromycin (AZM; Pﬁzer), and telithromycin (TEL;
Sanoﬁ-Aventis); a lincosamide clindamycin (CLDM; Dai-
nippon Sumitomo.); a tetracycline minocycline (MINO;
Wyeth/Takeda); two glycopeptides such as vancomycin
(VCM; Shionogi) and teicoplanin (TEIC; Astellas); six
ﬂuoroquinolones such as ciproﬂoxacin (CPFX; Bayer-
Yakuhin), levoﬂoxacin (LVFX; Daiichi-Sankyo), tosuﬂox-
acin (TFLX; Toyama), moxiﬂoxacin (MFLX; Shionogi),
pazuﬂoxacin (PZFX; Toyama) and garenoxacin (GRNX;
Astellas), and an oxazolidinone linezolide (LZD; Pﬁzer).
These antimicrobial agents were serially diluted and placed
under the freeze-dried state into the respective microplate
wells. The stability of the antimicrobial agent-containing
microplates was guaranteed by the manufacturer (Eiken
Kagaku) for 9 months.
Detection of b-lactamases
To detect b-lactamases in H. inﬂuenzae, tests with Nitor-
oceﬁn disks (Kanto Chemical, Tokyo, Japan) were
conducted according to the reference manual supplied by
the manufacturer.
A recently established rapid detection method, the Cica-
Beta Test 1 (Kanto Chemical), which was designed to
detect extended-spectrum b-lactamase (ESBL) and metal-
lo-b-lactamase (MBL) directly in colonies of gram-nega-
tive rods, was employed to identify the K. pneumoniae and
P. aeruginosa strains that produce such b-lactamases.
Statistical analysis
The categorical variables of the susceptibility of S. pneu-
moniae to PCG were summarized as percentages and
compared using a chi-square test or Fisher’s test when
appropriate. A P value \0.05 was considered to be
signiﬁcant.
Results
Staphylococcus aureus
The in vitro antimicrobial susceptibilities, as MIC50/MIC90
values, and the range of MICs for S. aureus isolates, are
shown in Table 2. Among the total 130 strains of S. aureus,
76 strains (58.5 %) were found to be methicillin-resistant
S. aureus (MRSA; MIC of MPIPC, C4 lg/ml).
Susceptibility of methicillin-susceptible S. aureus
(MSSA)
The MIC90 of penicillins against 54 MSSA strains was
16 lg/ml; however, the MIC90 of penicillins in combina-
tions with b-lactamase inhibitors (CVA/AMPC, SBT/
ABPC, and TAZ/PIPC) decreased to 1.0–4.0 lg/ml. The
MIC90s of CCL, CAZ, CTRX, CFPM, and CFX ranged
from 2.0 to 8.0 lg/ml and those of the other seven cephems
from 0.25 to 1.0 lg/ml. Carbapenems showed the strongest
activity, with MIC90s B0.125 lg/ml. As for aminoglyco-
sides, GM, TOB, AMK, and ABK showed MIC90 of 16.0,
8.0, 4.0, and 1.0 lg/ml, respectively. Among the macro-
lide-lincosamide antibiotics, TEL and CLDM showed rel-
atively strong activity with MIC90 of 0.125 and 0.25 lg/ml,
respectively, but the rest of the macrolides showed weak
activity with MIC90 C128 lg/ml. Relatively strong activ-
ities of MINO, VCM, TEIC, and LZD were shown, with
MIC90s of 0.25–2.0 lg/ml. MIC90s of the seven ﬂuoro-
quinolones were within the range of 0.25–8.0 lg/ml.
Susceptibility of MRSA
Only four agents, ABK, VCM, TEIC, and LZD, showed
strong activity against MRSA, with MIC90 B2.0 lg/ml.
612 J Infect Chemother (2012) 18:609–620
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Table 2 Antibacterial susceptibility of Staphylococcus aureus of the 130 strains of S. aureus to 44 antimicrobial agents measured
Antibacterial
agent
All strains, n = 130 MRSA, n = 76 MSSA, n = 54
MIC (lg/ml) MIC (lg/ml) MIC (lg/ml)
50 % 90 % Range 50 % 90 % Range 50 % 90 % Range
PCG 16 32 B0.06 to 128 16 64 8 to 128 0.25 16 B0.06 to 64
MPIPC 64 C256 0.125 to C256 128 C256 16 to C256 0.25 0.5 0.125 to 2
ABPC 16 64 B0.06 to 128 16 64 8 to 128 0.5 16 B0.06 to 32
SBT/ABPC 8 32 0.125 to 128 16 32 4 to 128 0.25 2 0.125 to 4
CVA/AMPC 16 32 0.125 to C128 32 32 2 to C128 0.25 1 0.125 to 2
PIPC 64 128 0.5 to C256 128 C256 32 to C256 1 16 0.5 to 64
TAZ/PIPC-1 32 128 0.5 to C256 64 C256 4 to C256 1 2 0.5 to 2
TAZ/PIPC-2 32 128 0.5 to C256 64 128 8 to C256 1 4 0.5 to 8
CCL 64 128 0.5 to C256 128 C256 8 to C256 1 2 0.5 to 4
CFDN 8 C128 0.125 to C128 C128 C128 1 to C128 0.25 0.5 0.125 to 1
CFPN C256 C256 0.5 to C256 C256 C256 4 to C256 1 1 0.5 to 2
CDTR 32 C128 0.25 to C128 64 C128 4 to C128 0.5 1 0.25 to 1
CEZ 64 C256 0.25 to C256 128 C256 1 to C256 0.25 0.5 0.25 to 1
CFX 32 C128 1 to C128 C128 C128 8 to C128 2 4 1 to 8
CMZ 8 64 0.5 to C256 32 64 4 to C256 1 1 0.5 to 1
CTM 32 C256 0.5 to C256 128 C256 2 to C256 0.5 1 0.5 to 1
CAZ C128 C128 8 to C128 C128 C128 16 to C128 8 8 8 to 16
CTRX C256 C256 2 to C256 C256 C256 8 to C256 4 4 2 to 8
CFPM 64 C256 1 to C256 128 C256 8 to C256 2 4 1 to 4
CZOP 8 64 0.5 to C256 32 64 2 to C256 1 1 0.5 to 2
IPM 1 32 B0.06 to C128 16 64 B0.06 to C128 B0.06 B0.06 B0.06
PAPM 1 16 B0.06 to 128 8 32 0.125 to 128 B0.06 B0.06 B0.06 to 0.125
MEPM 4 16 B0.06 to 128 16 32 0.25 to 128 B0.06 0.125 B0.06 to 0.125
BIPM 4 32 B0.06 to C256 16 64 0.125 to C256 B0.06 B0.06 B0.06 to 0.125
DRPM 2 16 B0.06 to C128 8 16 0.125 to C128 B0.06 B0.06 B0.06
FRPM 2 C256 B0.06 to C256 128 C256 0.125 to C256 0.125 0.125 B0.06 to 0.25
GM 0.5 64 0.125 to C256 16 128 0.125 to C256 0.25 16 0.125 to 64
TOB 32 C256 0.125 to C256 C256 C256 0.25 to C256 0.5 8 0.125 to 32
AMK 4 16 0.5 to C256 16 32 1 to C256 2 4 0.5 to 8
ABK 0.5 1 0.125 to 4 0.5 1 0.125 to 4 0.5 1 0.125 to 1
EM C256 C256 0.125 to C256 C256 C256 0.25 to C256 0.25 C256 0.125 to C256
CAM C128 C128 0.125 to C128 C128 C128 0.25 to C128 0.25 C128 0.125 to C128
AZM C128 C128 0.25 to C128 C128 C128 0.5 to C128 0.5 C128 0.25 to C128
TEL C128 C128 B0.06 to C128 C128 C128 B0.06 to C128 0.125 0.125 B0.06 to C128
CPFX 16 C256 0.125 to C256 128 C256 0.25 to C256 0.5 8 0.125 to C256
LVFX 4 C256 B0.06 to C256 16 C256 0.125 to C256 0.25 4 B0.06 to C256
TFLX 2 C32 B0.06 to C32 C32 C32 B0.06 to C32 B0.06 2 B0.06 to C32
MFLX 1 32 B0.06 to 64 4 32 B0.06 to 64 B0.06 1 B0.06 to 32
PZFX 4 C256 0.125 to C256 8 C256 0.125 to C256 0.125 4 0.125 to C256
GRNX 0.5 32 B0.06 to 64 1 64 B0.06 to 64 B0.06 0.5 B0.06 to 64
MINO 0.25 16 B0.06 to 16 16 16 0.125 to 16 0.125 0.25 B0.06 to 16
CLDM C256 C256 B0.06 to C256 C256 C256 0.125 to C256 0.125 0.25 B0.06 to C256
VCM 1 2 0.5 to 2 1 2 0.5 to 2 1 2 0.5 to 2
TEIC 0.5 1 0.125 to 4 0.5 2 0.125 to 4 0.5 1 0.25 to 2
LZD 2 2 1 to 4 2 2 1 to 4 2 2 1 to 4
The strains consist of 76 strains (58.5 %) of methicillin-resistant Staphylococcus aureus (MRSA) and 54 strains (41.5 %) of methicillin-susceptible Staphylococcus
aureus (MSSA)
PCG benzylpenicillin, MPIPC oxacillin, ABPC ampicillin, PIPC piperacillin, CVA/AMPC clavulanic acid-amoxicillin, SBT/ABPC sulbactam-ABPC, TAZ/PIPC
tazobactam-PIPC Toyama, TAZ/PIPC-1 piperacillin with 4 lg/mL of tazobactam, TAZ/PIPC-2 tazobactam : piperacillin = 1 : 8, CCL cefaclor, CFDN cefdinir,
CFPN cefcapene, CDTR cefditoren, CEZ cefazolin, CFX cefoxitin, CMZ cefmetazole, CTM cefotiam, CAZ ceftazidime, CTRX ceftriaxone, CFPM cefepime, CZOP
cefozopran, AZT aztreonam, IPM imipenem, PAPM panipenem, MEPM meropenem, BIPM biapenem, DRPM doripenem, FRPM faropenem, GM gentamicin, TOB
tobramycin, AMK amikacin, ABK arbekacin, EM erythromycin, CAM clarithromycin, AZM azithromycin, TEL telithromycin, CLDM clindamycin, MINO mino-
cycline, VCM vancomycin, TEIC teicoplanin, CPFX ciproﬂoxacin, LVFX levoﬂoxacin, TFLX tosuﬂoxacin, MFLX moxiﬂoxacin, PZFX pazuﬂoxacin, GRNX
garenoxacin, LZD linezolide
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MINO showed weak activity with MIC90 of 16 lg/ml.
Other agents showed almost no activity, with MIC90
C32 lg/ml.
Streptococcus pneumoniae
The susceptibilities of the 127 strains of S. pneumoniae to
PCG revealed that 119 strains (93.7 %), 8 strains (6.3 %),
and 0 strains (0.0 %) were identiﬁed as penicillin-suscep-
tible (PSSP), penicillin-intermediate (PISP), and penicillin-
resistant strains (PRSP), respectively, with the breakpoint
for PCG deﬁned by the CLSI standards. However, with the
previous susceptibility criteria for S. pneumoniae strains,
71 strains (55.9 %), 34 strains (26.8 %), and 22 strains
(17.3 %) were classiﬁed as susceptible (MIC of PCG
B0.06 lg/ml), intermediate (MIC of PCG 0.125–1 lg/ml),
and resistant (MIC of PCG C2 lg/ml) strains, respectively.
Among the b-lactams, CCL, CAZ, and CMZ showed
high MIC90s (64, 8, and 16 lg/ml, respectively), while
many of the other b-lactams, except for the carbapenems,
showed potent activities, with MIC90s of 1.0–4.0 lg/ml.
All ﬁve carbapenems showed strong activities (MIC90
B0.25 lg/ml) against all S. pneumoniae strains, regardless
of their different susceptibilities to PCG. Fluoroquinolones
also showed potent activities against most of the strains
with MIC90s of B0.25–4 lg/ml, although 7 strains (2.6 %)
were found to be resistant to LVFX. The glycopeptides
(VCM and TEIC) and TEL showed strong activities (MIC90
B0.5 lg/ml). Aminoglycosides were substantially less
active, with MIC90s of 8.0–64.0 lg/ml. High frequencies of
resistance against the macrolide antibiotics, EM, CAM, and
AZM, were shown, with MIC90s C64 lg/ml (Table 3).
Haemophilus inﬂuenzae
The susceptibilities of the 123 H. inﬂuenzae strains are
summarized in Table 4. According to the CLSI breakpoint
for ABPC, 67 (54.5 %) were found to be ABPC suscepti-
ble, 26 (21.1 %) to be ABPC intermediate, and 30 (24.4 %)
ABPC resistant. With the use of the Nitrocephin disks, all
ABPC-intermediate and 23 (18.7 %) ABPC-resistant
strains were found to be b-lactamase-non-producing, and
they were deﬁned as BLNAI and BLNAR, respectively.
The other 7 (5.7 %) ABPC-resistant strains were found to
be b-lactamase-producing strains, designated as BLPAR.
The MIC50 and MIC90 values of PCG and ABPC for
BLPAR isolates were at least threefold higher than those
for BLNAR isolates. However, there were no differences in
the MIC50 and MIC90 values of SBT/ABPC and CVA/
AMPC among BLNAR isolates and BLPAR isolates.
Regardless of susceptibility to ABPC, all the H. inﬂuenzae
strains were extremely susceptible to all six ﬂuoroquino-
lones (MIC50s B0.06 lg/ml). BLPAR strains showed high
levels of resistance against PIPC, with MIC90 values
C256 lg/ml, whereas TAZ/PIPC showed strong activities,
with MIC90s B0.125 lg/ml. Among the cephems, CDTR
and CTRX showed the most potent activities, with MIC90s
of 0.25 lg/ml. Of the ﬁve carbapenem agents, MEPM
showed the most potent acvitity against all types of
H. inﬂuenzae strains. Among macrolides and the ketolide,
AZM and TEL showed the most potent activity, with
MIC90s of 2 lg/ml.
Moraxella catarrhalis
The susceptibilities of 70 M. catarrhalis strains are shown
in Table 5. For the penicillins, b-lactamase inhibitors
restored the activities of penicillins; e.g., SBT decreased the
MIC90 of ABPC from 16 to 0.25 lg/ml and TAZ decreased
the MIC90 of PIPC from 16 to 0.125 lg/ml. Carbapenems
showed strong activities, with MIC90s B0.125 lg/ml.
Fluoroquinolones also showed strong activities, with
MIC90s B0.06 lg/ml. Several cephems (CFDN, CFPN,
CDTR, CAZ, and CMZ), four aminoglycosides (GM, TOB,
AMK, and ABK), three macrolides (EM, CAM, and AZM),
and the ketolide (TEL) also showed potent activities, with
the MIC90s of 0.125–1.0 lg/ml.
Klebsiella pneumoniae
The susceptibilities of 78 K. pneumoniae strains are shown
in Table 6. Carbapenems showed strong activities, with
MIC90s B0.5 lg/ml; in particular, MEPM and DRPM
showed the most potent activities, with MIC90s B0.06 lg/ml.
Of the cephems and the monobactam, CZOP showed the
most potent activity, with MIC90s B0.06 lg/ml, and
CFDN, CTM, CAZ, CTRX, CFPM, and AZT also showed
strong activities, with MIC90s of 0.125–0.25 lg/ml. All
ﬂuoroquinolones we tested and three aminoglyco-
sides (GM, TOB and ABK) showed potent activities,
with MIC90s of B0.25–0.5 lg/ml. b-lactamase inhibitors
apparently restored the activities of penicillins; e.g., SBT
decreased the MIC90 of ABPC from 128 to 8 lg/ml and
TAZ decreased the MIC90 of PIPC from 8 to 4 lg/ml.
Among 78 strains of K. pneumoniae, 1 strain (1.3 %) was
found to be an ESBL producer.
Pseudomonas aeruginosa
A total 103 P. aeruginosa strains were tested for antimi-
crobial susceptibility (Table 7). Among the b-lactams,
three carbapenems (MEPM, BIPM, and DRPM) showed
potent activities, with MIC50s of 0.25–0.5 lg/ml; however,
these agents showed relatively higher MIC90 levels,
8.0–16 lg/ml. Among the ﬂuoroquinolones, CPFX showed
the most potent activity, with MIC50s and MIC90s of 0.25
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Table 3 Antibacterial susceptibility of Streptococcus pneumoniae
Antibacterial agent All strains, n = 127 PSSP, n = 119 PISP, n = 8
MIC (lg/ml) MIC (lg/ml) MIC (lg/ml)
50 % 90 % Range 50 % 90 % Range 50 % 90 % Range
PCG B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 to 2 4 4 4 to 4
ABPC B0.06 2 B0.06 to 8 B0.06 B0.06 B0.06 to 4 2 8 2 to 8
SBT/ABPC B0.06 4 B0.06 to 8 B0.06 B0.06 B0.06 to 4 4 8 2 to 8
CVA/AMPC B0.06 1 B0.06 to 8 B0.06 B0.06 B0.06 to 2 4 8 0.5 to 8
PIPC B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 to 4 2 4 1 to 4
TAZ/PIPC-1 B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 to 4 2 4 1 to 4
TAZ/PIPC-2 B0.06 2 B0.06 to 4 B0.06 0.125 B0.06 to 4 2 4 1 to 4
CCL 1 64 0.25 to 128 1.0 64 0.25 to 128 64 128 32 to 128
CFDN 0.25 4 B0.06 to 32 0.25 4 B0.06 to 16 8 32 4 to 32
CFPN 0.25 1 0.125 to 32 0.25 1 0.125 to 2 2 32 0.5 to 32
CDTR 0.125 0.5 B0.06 to 4 0.125 0.5 B0.06 to 2 0.5 4 0.5 to 4
CEZ 0.125 4 B0.06 to 16 0.125 2 B0.06 to 8 4 16 4 to 16
CMZ 0.5 16 B0.06 to 32 0.5 8 B0.06 to 32 16 32 8 to 32
CTM 0.25 4 B0.06 to 16 0.25 4 B0.06 to 8 8 16 4 to 16
CAZ 4 8 0.125 to 64 4 8 0.125 to 32 16 64 8 to 64
CTRX 0.25 1 B0.06 to 8 0.25 1 B0.06 to 2 1 8 0.5 to 8
CFPM 0.5 1 B0.06 to 8 0.5 1 B0.06 to 2 2 8 1 to 8
CZOP 0.25 1 B0.06 to 16 0.25 1 B0.06 to 2 2 16 1 to 16
IPM B0.06 0.25 B0.06 to 0.5 B0.06 0.125 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
PAPM B0.06 B0.06 B0.06 to 0.25 B0.06 B0.06 B0.06 to 0.25 B0.06 0.25 B0.06 to 0.25
MEPM B0.06 0.25 B0.06 to 0.5 B0.06 0.25 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
BIPM B0.06 0.25 B0.06 to 0.5 B0.06 0.25 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
DRPM B0.06 0.25 B0.06 to 0.5 B0.06 0.125 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
FRPM B0.06 0.25 B0.06 to 0.5 B0.06 0.25 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
GM 4 8 2 to 16 4 8 2 to 16 4 16 4 to 16
TOB 16 16 4 to 32 16 16 4 to 32 16 32 8 to 32
AMK 32 64 16 to 128 32 64 16 to 128 32 64 32 to 64
ABK 16 32 8 to 64 16 32 8 to 64 16 64 16 to 64
EM C128 C128 B0.06 to C128 C128 C128 B0.06 to C128 C128 C128 B0.06 to C128
CAM C64 C64 B0.06 to C64 C64 C64 B0.06 to C64 C64 C64 B0.06 to C64
AZM C64 C64 B0.06 to C64 C64 C64 B0.06 to C64 C64 C64 B0.06 to C64
TEL B0.06 0.25 B0.06 to 2 B0.06 0.25 B0.06 to 2 B0.06 0.5 B0.06 to 0.5
CPFX 1 2 B0.06 to 64 1 2 B0.06 to 64 1 2 0.25 to 2
LVFX 1 2 B0.06 to 64 1 2 B0.06 to 64 1 1 0.5 to 1
TFLX 0.125 0.25 B0.06 to C16 0.25 0.25 B0.06 to C16 0.125 0.25 B0.06 to 0.25
MFLX 0.125 0.25 B0.06 to 8 0.125 0.25 B0.06 to 8 0.125 0.25 0.125 to 0.25
PZFX 2 4 1 to 128 2 4 1 to 128 2 4 2 to 4
GRNX B0.06 B0.06 B0.06 to 2 B0.06 B0.06 B0.06 to 2 B0.06 B0.06 B0.06 to B0.06
MINO 8 16 B0.06 to 64 8 16 B0.06 to 64 8 16 B0.06 to 16
CLDM 64 C128 B0.06 to C128 64 C128 B0.06 to C128 C128 C128 B0.06 to C128
VCM 0.25 0.5 0.125 to 0.5 0.25 0.5 0.125 to 0.5 0.5 0.5 0.25 to 0.5
TEIC B0.06 0.125 B0.06 to 0.125 B0.06 0.125 B0.06 to 0.125 B0.06 0.125 B0.06 to 0.125
LZD 1 1 0.125 to 2 1 1 0.125 to 2 1 2 0.5 to 2
Susceptibilities of the 127 strains of S. pneumoniae to 42 antimicrobial agents were studied. The number of strains and proportion of penicillin-
susceptible (PSSP), penicillin-intermediate (PISP), and penicillin-resistant (PRSP) are 119 (93.7 %), 8 (6.3 %), and 0 (0.0 %), respectively
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Table 4 Antibacterial susceptibility of Haemophilus inﬂuenzae
Antibacterial agent All strains, n = 123 BLNAS [ABPC B 1,
b-lactamase(-)], n = 67
BLNAI [ABPC = 2,
b-lactamase(-)], n = 26
BLNAR [ABPC C 4,
b-lactamase(-)], n = 23
b-lactamase(?), n = 7
MIC (lg/ml) MIC (lg/ml) MIC (lg/ml) MIC (lg/ml) MIC lg/ml)
50 % 90 % Range 50 % 90 % Range 50 % 90 % Range 50 % 90 % Range 50 % 90 % Range
PCG 4 8 0.25 to C256 1 4 0.25 to 8 4 8 2 to 8 8 8 4 to 16 C256 C256 32 to C256
ABPC 1 4 0.125 to C256 0.5 1 0.125 to 1 2 2 2 4 8 4 to 8 C256 C256 32 to C256
SBT/ABPC 2 8 0.125 to 8 0.5 2 0.125 to 2 2 4 2 to 4 4 8 4 to 8 8 8 1 to 8
CVA/AMPC 2 8 0.25 to 16 0.5 2 0.25 to 8 4 8 1 to 8 8 8 2 to 16 8 8 1 to 8
PIPC B0.06 0.25 B0.06 to C256 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 128 C256 8 to C256
TAZ/PIPC-1 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.125
TAZ/PIPC-2 B0.06 0.25 B0.06 to 1 B0.06 0.125 B0.06 to 0.25 B0.06 0.25 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 1 1 0.25 to 1
CCL 16 64 0.25 to 128 4 32 0.25 to 64 16 64 4 to 64 32 64 4 to 128 32 128 2 to 128
CFDN 2 8 B0.06 to 16 0.5 4 B0.06 to 8 2 8 0.5 to 8 4 8 1 to 16 2 4 0.25 to 4
CFPN 0.5 2 B0.06 to 8 B0.06 1 B0.06 to 4 1 2 0.125 to 4 2 4 0.5 to 8 1 2 B0.06 to 2
CDTR B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 to 0.25 0.125 0.25 B0.06 to 0.5 0.25 0.25 B0.06 to 0.5 0.125 0.25 B0.06 to 0.25
CEZ 4 64 0.5 to C256 4 16 0.5 to 128 4 16 1 to 32 16 128 2 to C256 32 128 4 to 128
CMZ 8 16 0.25 to 64 4 8 0.25 to 32 8 16 2 to 32 16 32 4 to 64 8 16 2 to 16
CTM 4 32 0.25 to 64 2 16 0.25 to 64 8 32 1 to 64 32 64 4 to 64 16 64 1 to 64
CAZ 0.25 0.5 B0.06 to 2 0.125 0.5 B0.06 to 1 0.25 1 0.125 to 2 0.25 0.5 0.25 to 2 0.25 2 0.25 to 2
CTRX 0.125 0.25 B0.06 to 0.5 B0.06 0.25 B0.06 to 0.5 0.25 0.25 B0.06 to 0.25 0.25 0.25 B0.06 to 0.5 0.25 0.5 B0.06 to 0.5
CFPM 1 2 B0.06 to 4 0.25 1 B0.06 to 2 2 4 0.25 to 4 2 2 0.5 to 4 2 2 0.25 to 2
CZOP 4 16 B0.06 to 32 0.25 8 B0.06 to 8 8 16 1 to 16 8 16 2 to 32 8 32 0.25 to 32
IPM 0.5 2 B0.06 to 4 0.5 1 B0.06 to 4 0.5 2 0.125 to 4 1 2 0.5 to 4 1 4 0.5 to 4
PAPM 0.5 2 B0.06 to 8 0.5 1 B0.06 to 2 0.5 2 B0.06 to 8 1 2 0.5 to 2 1 2 0.25 to 2
MEPM B0.06 0.25 B0.06 to 1 B0.06 0.125 B0.06 to 0.25 0.125 0.25 B0.06 to 0.5 0.25 0.5 B0.06 to 1 0.125 0.25 B0.06 to 0.25
BIPM 1 4 B0.06 to 8 0.5 4 B0.06 to 8 2 4 B0.06 to 8 4 8 1 to 8 2 8 1 to 8
DRPM 0.125 1 B0.06 to 2 0.125 0.25 B0.06 to 1 0.25 1 B0.06 to 2 1 2 B0.06 to 2 0.5 0.5 0.125 to 0.5
FRPM 1 2 0.125 to 4 0.5 2 0.125 to 4 2 2 0.5 to 4 2 4 0.5 to 4 2 2 0.5 to 2
AZT 0.5 2 B0.06 to 8 B0.06 1 B0.06 to 2 0.5 2 B0.06 to 4 1 2 0.25 to 4 0.5 8 0.125 to 8
GM 1 1 0.125 to 4 1 1 0.125 to 4 1 1 0.25 to 2 1 1 0.5 to 2 1 2 0.5 to 2
TOB 2 2 0.5 to 8 2 2 0.5 to 8 2 2 0.5 to 4 2 2 1 to 4 2 4 1 to 4
AMK 4 8 0.5 to 8 4 8 0.5 to 8 4 8 1 to 8 4 8 2 to 8 4 8 2 to 8
ABK 2 4 0.5 to 8 2 4 0.5 to 8 2 4 1 to 4 2 4 1 to 4 2 4 1 to 4
EM 4 8 0.125 to 16 4 8 0.125 to 16 2 4 1 to 8 4 8 1 to 8 2 4 2 to 4
CAM 8 8 0.125 to 32 4 8 0.125 to 32 4 8 2 to 16 8 16 4 to 16 8 8 4 to 8
AZM 0.5 2 B0.06 to 4 0.5 2 B0.06 to 4 0.5 1 0.25 to 2 1 2 0.25 to 2 0.5 2 0.5 to 2
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and 8.0 lg/ml, respectively. Other ﬂuoroquinolones also
showed strong activities with MIC50s of 0.5–4.0 lg/ml,
whereas MIC90 levels (8.0 to C32 lg/ml) suggested partial
resistance. Both PIPC and TAZ/PIPC showed potent
activities, with MIC50s of 4.0 lg/ml; the higher levels of
MIC90s (C256 and 128 lg/ml) of these agents suggested
resistance. The MIC50s of the four aminoglycosides (GM,
TOB, AMK, and ABK), three cephems (CAZ, CFPM, and
CZOP), and the monobactam (AZT) were within the range
0.5–4.0 lg/ml. Among the 103 P. aeruginosa strains, we
found 2 MBL-producing strains (1.9 %) and 3 multidrug-
resistant strains (2.9 %).
Discussion
The JSC established a nationwide surveillance network in
2006 to establish the resource of information about anti-
microbial susceptibility of bacterial pathogens in Japan.
Our research focuses on major seven major bacterial
respiratory pathogens, that is, S. aureus, S. pneumoniae,
S. pyogenes, H. inﬂuenzae, M. catarrhalis, K. pneumoniae,
and P. aeruginosa. It is desirable that analysis of antimi-
crobial susceptibility is carried out using the bacterial
strains that actually cause the infections. To analyze the
actual pathogens causing infections, we collected clinical
isolates only from well-diagnosed adult patients with RTIs.
Our surveillance was conducted for 4 consecutive years
from 2006. The total number of strains at surveillance
conducted in 2006, 2007, 2008, and 2009 were 887, 1108,
987, and 635, respectively. Each species tested at surveil-
lance in every year are as follows: S. aureus (205, 226, 189,
and 130), S. pneumoniae (200, 257, 211, and 127), H. in-
ﬂuenzae (165, 206, 187, and 123), P. aeruginosa (143, 171,
162, and 103), M. catarrhalis (91, 120, 106, and 70),
K. pneumoniae (74, 122, 126, and 78), and S. pyogenes
(9, 6, 6, and 4). The numbers of each species in each year
of surveillance may generally reﬂect the trend of pathogens
of respiratory infections in Japan, but we think we should
increase the scope of the survey by reporting results with a
greater number of pathogens.
With regard to S. aureus, 28 of 54 strains (51.8 %) of
MSSA were thought to be penicillinase-producing strains
because of their resistance to ABPC and susceptibility to
SBT/ABPC and CCL, and 3 of 54 strains (5.6 %) of MSSA
may be emr-harboring strains because of their resistance to
the macrolides EM, CAM, and AZM and susceptibility to
TEL (ketolide lacking emr resistance mechanism) [4]. The
difference between resistance of MSSA against GM
(11.1 %) and that against AMK (0 %) implied that major
aminoglycoside-resistant strains were not aad(40, 400)-har-
boring AMK-resistant strains but aac(60)/aph(200)-harbor-
ing GM-resistant strains [5].T
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The incidence of MRSA was as high as 58.5 %, which is
similar to the data reported by Mochizuki et al. [6] under
the analyses via WHONET 5. These MRSA strains are
susceptible to ABK, VCM, TEIC, and LZD, except that a
few strains which are somewhat less susceptible (MIC
8.0 lg/ml) to ABK may possess both aph(30)-III and
aac(60)/aph(200) genes, as reported recently [5]. Although
Table 5 Antibacterial susceptibility of Moraxella catarrhalis
Antibacterial agent MIC (lg/ml)
50 % 90 % Range
PCG 16 32 B0.06 to 64
ABPC 8 16 B0.06 to 32
SBT/ABPC 0.125 0.25 B0.06 to 0.5
CVA/AMPC 0.25 0.25 B0.06 to 0.5
PIPC 2 16 B0.06 to 32
TAZ/PIPC-1 B0.06 B0.06 B0.06
TAZ/PIPC-2 0.125 0.125 B0.06 to 0.125
CCL 2 8 0.125 to 32
CFDN 0.25 0.5 B0.06 to 1
CFPN 0.5 1 B0.06 to 4
CDTR 0.5 1 B0.06 to 2
CEZ 4 16 0.125 to 64
CMZ 0.5 1 B0.06 to 4
CTM 1 2 0.25 to 4
CAZ 0.25 0.5 B0.06 to 2
CTRX 1 2 B0.06 to 4
CFPM 1 4 B0.06 to 8
CZOP 2 8 B0.06 to 8
IPM B0.06 0.125 B0.06 to 0.25
PAPM B0.06 B0.06 B0.06 to 0.125
MEPM B0.06 B0.06 B0.06
BIPM B0.06 B0.06 B0.06 to 0.125
DRPM B0.06 B0.06 B0.06
FRPM 0.5 0.5 B0.06 to 1
AZT 2 4 0.125 to 8
GM 0.125 0.125 B0.06 to 0.25
TOB 0.25 0.25 B0.06 to 0.5
AMK 0.5 1 B0.06 to 2
ABK 0.125 0.25 B0.06 to 0.5
EM 0.125 0.25 B0.06 to 0.5
CAM 0.125 0.25 B0.06 to 0.5
AZM B0.06 B0.06 B0.06
TEL 0.125 0.25 B0.06 to 0.25
CPFX B0.06 B0.06 B0.06 to 0.125
LVFX B0.06 B0.06 B0.06 to 2
TFLX B0.06 B0.06 B0.06
MFLX B0.06 B0.06 B0.06 to 0.5
PZFX B0.06 B0.06 B0.06 to 2
GRNX B0.06 B0.06 B0.06 to 0.25
MINO 0.125 0.25 B0.06 to 1
CLDM 2 4 0.5 to 8
VCM 64 128 32 to 128
TEIC 16 32 8 to 32
LZD 8 8 2 to 16
Susceptibilities of the 70 strains of M. catarrhalis to 40 antimicrobial
agents were studied
Table 6 Antibacterial susceptibility of Klebsiella pneumoniae
Antibacterial agent MIC (lg/ml)
50 % 90 % Range
ABPC 32 128 8 to C256
SBT/ABPC 4 8 2 to 32
CVA/AMPC 2 4 0.5 to 16
PIPC 4 8 0.5 to C256
TAZ/PIPC-1 2 4 B0.06 to 32
TAZ/PIPC-2 2 4 0.25 to 32
CCL 0.5 1 0.125 to C256
CFDN 0.125 0.25 B0.06 to C128
CFPN 0.5 1 B0.06 to 32
CDTR 0.125 0.5 B0.06 to C128
CEZ 1 2 0.5 to C256
CMZ 0.5 1 0.25 to 64
CTM 0.125 0.25 B0.06 to C256
CAZ 0.125 0.25 B0.06 to 64
CTRX B0.06 0.125 B0.06 to 64
CFPM B0.06 0.125 B0.06 to 8
CZOP B0.06 B0.06 B0.06 to 32
IPM 0.125 0.5 B0.06 to 1
PAPM 0.125 0.5 B0.06 to 0.5
MEPM B0.06 B0.06 B0.06 to 0.125
BIPM 0.125 0.5 B0.06 to 1
DRPM B0.06 B0.06 B0.06 to 0.125
FRPM 0.5 0.5 0.125 to 32
AZT B0.06 0.125 B0.06 to 4
GM 0.25 0.25 B0.06 to 0.5
TOB 0.5 0.5 B0.06 to 8
AMK 1 1 0.125 to 2
ABK 0.5 0.5 B0.06 to 0.5
AZM 8 16 1 to 64
CPFX B0.06 B0.06 B0.06 to 4
LVFX B0.06 0.25 B0.06 to 4
TFLX B0.06 B0.06 B0.06 to 8
MFLX 0.125 0.5 B0.06 to 8
PZFX B0.06 B0.06 B0.06 to 2
GRNX B0.06 0.25 B0.06 to 8
MINO 2 4 0.25 to 64
Susceptibilities of the 78 strains of K. pneumoniae to 35 antimicrobial
agents were studied
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the emergence of resistant MRSA against VCM, TEIC, or
LZD has already been reported in Japan, such a resistant
strain was not detected in this surveillance.
In the previous criteria, the concentration at which
S. pneumoniae is considered to be susceptible to penicillin
for the treatment of pneumonia was determined by refer-
ence to the susceptibility breakpoint for meningitis
(0.06 lg/ml). In this surveillance, the susceptibility of
S. pneumoniae to PCG was categorized with the new cri-
teria of breakpoint MICs (MIC of PCG: PSSP B2, PISP 4,
PRSP C8), and the proportion of PSSP/PISP/PRSP was
found to be 94:6:0. These results suggest that penicillin is
still effective against community-acquired pneumonia
caused by S. pneumoniae but that some penicillin-inter-
mediate strains are present. Among PSSP, more than 85 %
are thought to be erm-harboring strains because of their
resistance to macrolides (EM, CAM, and AZM) and
CLDM and susceptibility to the ketolide TEL.
To understand the trend of the susceptibility of
S. pneumoniae to PCG, we also compared the incidence of
the S. pneumoniae isolation in each year with the previous
criteria (MIC of PCG: PSSP B0.06, PISP 0.125–1, PRSP
C2). Although the proportions of PSSP/PISP/PRSP of 2006
and 2007 were at a similar level (61:35:4 and 65:30:5,
respectively), the susceptibility of S. pneumoniae to PCG
seems to have decreased in 2008 and 2009 (53:35:12 and
56:27:17, respectively). In particular, the frequency of
PRSP, increased from 11.8 % in 2008 to 17.3 % in 2009.
In comparison to 2006, the statistical difference of the
frequency of PRSP in 2008 and in 2009 was at P = 0.006
and at P = 0.0001, respectively. Because it is difﬁcult to
detect these alarming trends by the new criteria of break-
point MICs, careful watching using the previous criteria is
continuously needed.
Concerning H. inﬂuenzae, half the strains in the present
survey showed decreased susceptibility to ABPC without
production of b-lactamase; i.e., BLNAI (21.1 %) and
BLNAR (18.7 %). The incidence of BLNAI in adults is
thought to be somewhat lower (30.4 %) than that in chil-
dren [7]. All six ﬂuoroquinolones demonstrated extremely
strong activity (MIC90 B0.06 lg/ml) against H. inﬂuenzae
strains, regardless of their ABPC susceptibility. Among the
other agents, PIPC, TAZ/PIPC, CDTR, CTRX, and MEPM
showed strong activities (MIC90s of 0.125–0.25 lg/ml)
against BLNAS, BLNAI, and BLNAR strains. TAZ
markedly restored the activity of PIPC against BLPAR
(MIC90 decreased from C256 lg/ml to 0.125 lg/ml).
The susceptibilities of M. catarrhalis in the present
survey showed that b-lactamase inhibitors restored the
activities of penicillins against these strains: SBT decreased
the MIC90 of ABPC from 16 to 0.25 lg/ml. The data sug-
gest that most of the strains were resistant to penicillins
because of b-lactamase production. For the treatment of M.
catarrhalis infections, carbapenems, macrolides, and ﬂuo-
roquinolones may be recommended because these drugs
showed strong activities, with MIC90s B0.06–0.25 lg/ml.
The prevalence of ESBL strains has become a concern
in recent years. Yagi et al. [8] conducted a survey of ES-
BLs among 9,794 K. pneumoniae clinical isolates in Japan
during the period January 1997 to January 1998, and they
reported that 34 isolates (0.3 %) had been found to produce
ESBLs. However, an increase in the number of ESBL-
producing strains has been suggested; Yamaguchi et al. [9]
reported the results of a nationwide surveillance of anti-
bacterial activity of clinical isolates in 2009, and 3.3 % (3
of 91 strains) of K. pneumoniae were found to be ESBL-
producing strains. In our study, 1 of 78 strains (1.3 %) of K.
pneumoniae were found to be ESBL-producing strains, and
the results were consistent with previous reports.
In the present survey, 2 (1.9 %) metallo-b-lactamase
(MBL)-producing strains and 3 (2.9 %) multidrug-resistant
strains were found in 103 P. aeruginosa isolates. Yamag-
uchi et al. compared the frequencies of multidrug-resistant
strains of P. aeruginosa between isolates from the urinary
Table 7 Antibacterial susceptibility of Pseudomonas aeruginosa
Antibacterial agent MIC (lg/ml)
50 % 90 % Range
PIPC 4 C256 0.5 to C256
TAZ/PIPC-1 4 128 0.125 to C256
TAZ/PIPC-2 4 128 0.25 to C256
CAZ 2 32 0.5 to C128
CTRX 32 C256 1 to C256
CFPM 4 32 0.25 to C256
CZOP 2 32 0.125 to C256
IPM 1 16 B0.06 to 64
PAPM 4 32 0.25 to 128
MEPM 0.5 16 B0.06 to C256
BIPM 0.25 16 B0.06 to 128
DRPM 0.25 8 B0.06 to C128
AZT 4 32 0.125 to C256
GM 1 8 B0.06 to C256
TOB 0.5 2 B0.06 to C256
AMK 2 8 0.125 to 64
ABK 1 8 0.125 to 32
CPFX 0.25 8 B0.06 to 128
LVFX 1 16 B0.06 to C256
TFLX 0.5 C32 B0.06 to C32
MFLX 4 16 B0.06 to C256
PZFX 0.5 8 B0.06 to C256
GRNX 2 32 B0.06 to C256
MINO 16 64 0.5 to C256
Susceptibilities of the 103 strains of P. aeruginosa to 23 antimicrobial
agents were analyzed
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tract infections and those of RTIs; they reported 5.6 % and
1.8 % of multidrug-resistant strains were found from the
urinary isolates and the respiratory isolates, respectively.
Therefore, a low incidence of multidrug-resistant P. aeru-
ginosa may be limited to respiratory infections [10].
We think our surveillance data will be a useful reference
for the treatment of respiratory infections in our country.
There is substantial evidence that the overuse of antibiotics
is a major cause for the emergence of resistance in respi-
ratory pathogens. To prevent the further spread of antimi-
crobial resistance in respiratory pathogens, proper
antibiotic use is necessary. We should also continue the
surveillance to determine the actual situation of the resis-
tance shown by bacterial respiratory pathogens to antimi-
crobial agents.
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